The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The current state of treatment for limited-stage DLBCL
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses the current state of treatment for limited-stage diffuse large B-cell lymphoma (DLBCL), where short-term chemoimmunotherapy is often used with or without subsequent radiotherapy. Prof. Vitolo highlights the FLYER study (NCT00278421), where radiotherapy was not required for patients with non-Hodgkin lymphoma who achieved PET-negativity following R-CHOP plus rituximab. Prof. Vitolo also briefly compares the treatment of limited-stage DLBCL and advanced-stage DLBCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
